InvestorsHub Logo
Followers 0
Posts 31
Boards Moderated 0
Alias Born 10/25/2016

Re: None

Saturday, 04/01/2017 9:34:45 PM

Saturday, April 01, 2017 9:34:45 PM

Post# of 8473
By all appearances, Rprx is positioning itself for sale. Everybody is setting up to get paid. BODs all recently got 40K shares, CFO is getting 60K shares, Joe got $2.7M severance package, new CEO will get 50K shares with FDA green light for Proellex in April. Looks like they are not going to release enclomiphene P2b results until after May 15th, the 15 month completion date. If all goes well with EU, approval could come in Aug. With est. $4M cash after Q1, and est. $6M ATM shares left, funding should last into Q3. "If" big pharma comes in and takes both drugs to approval, it will be par for the course. It just goes to show how difficult it is for a small biotech to pull it off, NO mistakes. "If" all goes down with a buy out, the investors that profit will be longs that averaged down, or recent and new investors that bought in when share price was depressed.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RPRX News